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PLINICAL RESEARCH Interventional Cardiology
mpact of the Degree of
eri-Interventional Platelet Inhibition After
oading With Clopidogrel on Early Clinical
utcome of Elective Coronary Stent Placement
illibald Hochholzer, MD,* Dietmar Trenk, PHD,* Hans-Peter Bestehorn, MD,* Benjamin Fischer,*
hristian M. Valina, MD,* Miroslaw Ferenc, MD,* Michael Gick, MD,* Angelika Caputo, PHD,†
einz Joachim Büttner, MD,* Franz-Josef Neumann, MD*
ad Krozingen and Freiburg, Germany
OBJECTIVES Our prospective study tested the hypothesis that the 30-day clinical outcome of elective
percutaneous catheter intervention (PCI) differs between strata defined by quartiles of platelet
aggregation after loading with 600 mg clopidogrel.
BACKGROUND Platelet responses after loading with clopidogrel are highly variable. The impact of this
variability on the peri-interventional risk of patients undergoing PCI has not been investi-
gated prospectively.
METHODS Our study included 802 consecutive patients undergoing elective coronary stent placement.
Before PCI, patients received a loading dose of 600 mg clopidogrel followed by 75 mg daily.
Primary end point was the 30-day composite of death, myocardial infarction, and target lesion
revascularization (major adverse cardiac events [MACE]). Platelet aggregation was assessed
immediately before PCI by optical aggregometry (5 mol/l adenosine diphosphate).
RESULTS During 30-day follow-up, 15 patients (1.9%) incurred MACE (3 deaths, 8 myocardial
infarctions, 8 target lesion revascularizations). Quartiles of platelet aggregation were4%, 4%
to 14%, 15% to 32%, and 32%. Thirty-day MACE differed significantly (p  0.034)
between quartiles of platelet aggregation. It was 0.5% in the first quartile, 0.5% in the second,
3.1% in the third, and 3.5% in the fourth. Platelet aggregation above the median carried a
6.7-fold risk (95% confidence interval 1.52 to 29.41; p  0.003) of 30-day MACE.
Multivariable logistic regression analysis, including pertinent covariables, confirmed platelet
aggregation as a significant independent predictor of 30-day MACE (adjusted odds ratio per
10% increase in platelet aggregation 1.32, 95% confidence interval 1.04 to 1.61; p  0.026).
CONCLUSIONS The level of platelet aggregation immediately before elective coronary stenting in patients
pre-treated with a high loading dose of clopidogrel is correlated with early outcome after the
procedure. (J Am Coll Cardiol 2006;48:1742–50) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.065Cardiology Foundation
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rlatelet inhibition during percutaneous catheter interven-
ion (PCI) reduces the risk of early complications, in
articular, peri-interventional myocardial infarction (MI)
nd the need for emergency reintervention. This has been
hown consistently by studies on peri-interventional admin-
stration of glycoprotein (GP) IIb/IIIa antagonists (1,2)
See page 1751
nd, more recently, by studies on pre-treatment with thien-
pyridines (3,4). The benefit from peri-interventional GP
Ib/IIIa receptor blockade is critically dependent on the
evel of platelet inhibition achieved: In the GOLD (AU—
ssessing Ultegra) study, the quartile of patients with the
From the *Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany; and the
Institut für Medizinische Biometrie und Medizinische Informatik, University of
reiburg, Freiburg, Germany. Supported by a grant from the Herz-Zentrum Bad
rozingen.t
Manuscript received December 8, 2005; revised manuscript received May 30, 2006,
ccepted June 6, 2006.owest level of peri-interventional platelet inhibition (i.e.,
95% inhibition of platelet aggregation), had a more than
-fold increase in early (7 days) major adverse cardiac
vents (MACE) (composite of death, myocardial infarction,
nd urgent target vessel revascularization) (5).
The ISAR-REACT (Intracoronary Stenting and Anti-
hrombotic Regimen—Rapid Early Action for Coronary
reatment) and ISAR-SWEET (Intracoronary Stenting and
ntithrombotic Regimen: Is Abciximab a Superior Way to
liminate Elevated Thrombotic Risk in Diabetics) trials dem-
nstrated that pre-treatment with a 600-mg loading dose of
lopidogrel can replace peri-interventional GP IIb/IIIa recep-
or blockade in low- to intermediate-risk PCI (6,7). The
latelet response to this loading dose is, however, highly
ariable (8–10), and there is considerable concern that patients
ith a low or absent response to clopidogrel might be at
ncreased risk of complications. Several criteria for such non-
esponder status have been suggested (11,12), but none of
hem have been validated clinically.
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November 7, 2006:1742–50 Effect of Clopidogrel Loading and Risk of PCITo explore this issue, we conducted the EXCELSIOR
Impact of Extent of Clopidogrel-Induced Platelet Inhibi-
ion During Elective Stent Implantation on Clinical Event
ate) study. This prospective observational study investi-
ated the impact of the variability in peri-interventional
latelet function on the clinical outcome of patients under-
oing low to intermediate-risk PCI. Similarly to a previous
tudy (13), we focused on absolute values of platelet reac-
ivity rather than change from baseline. We hypothesized
hat a low level of platelet reactivity at the time of PCI was
eneficial, irrespective of whether this was due to pharma-
ologic inhibition or to low baseline platelet aggregation.
pecifically, we tested the hypothesis that the composite
0-day incidence of MACE differs by quartiles of the level
f adenosine diphosphate (ADP)-induced platelet aggrega-
ion after loading with 600 mg clopidogrel. The reasons to
dminister a loading dose of 600 mg instead of the previ-
usly widely accepted dose of 300 mg (4,14) were that this
as been: 1) used in large-scale clinical studies (6,7,15);
) shown to be safe (6,7,15,16); 3) shown to be more
ffective on platelet inhibition (9,17); and 4) associated with
etter clinical outcomes (18).
ETHODS
atient selection and interventions. Patients undergoing
lective coronary stent placement after pre-treatment with
00 mg clopidogrel and aspirin (100 mg per day for at
east 5 days) were eligible for the study. We screened
atients scheduled for cardiac catheterization as potential
andidates for PCI. Major exclusion criteria were acute MI
ccording to the American Heart Association/American
ollege of Cardiology (AHA/ACC) criteria, chronic oral
nticoagulation, thienopyridine treatment within the last 2
eeks before admission, contraindications to aspirin, clopi-
ogrel, or heparin, cancer, hemodialysis, and hemodynamic
nstability. All patients gave written informed consent. The
tudy was approved by the ethics committee of the medical
aculty of the University of Freiburg, Germany.
Before the intervention, all patients were on aspirin and
eceived a loading dose of 600 mg clopidogrel. Catheteriza-
Abbreviations and Acronyms
ADP  adenosine diphosphate
AHA/ACC  American Heart Association/
American College of Cardiology
EXCELSIOR  Impact of Extent of Clopidogrel-
Induced Platelet Inhibition During
Elective Stent Implantation on Clinical
Event Rate
GP  glycoprotein
MACE  major adverse cardiac event
MI  myocardial infarction
PCI  percutaneous catheter intervention
TIMI  Thrombolysis In Myocardial Infarctionion was timed according to the routine schedule of the catheterization laboratory. A delay of at least 2 h between
lopidogrel loading and catheterization was strongly recom-
ended. Noncompliance with this recommendation, how-
ver, did not preclude participation in the study. The choice
f stent type was left to the operator’s discretion. All
atients received an intra-arterial dose of 100 to 140 U/kg
eparin; GP IIb/IIIa inhibitors were not allowed except for
ail-out in case of extensive dissection or thrombus forma-
ion with deterioration of coronary flow to Thrombolysis In
yocardial Infarction (TIMI) flow grade2. After PCI, all
atients received aspirin (100 mg/day) and 75 mg/day
lopidogrel for the duration of the study.
latelet function assays. Immediately after inclusion
n the study, blood was drawn for platelet function assays
sing tubes containing 3.8% sodium citrate (Sarstedt, Nüm-
recht, Germany). We obtained the second blood sample at
he time of catheterization before administration of heparin
r contrast medium.
Platelet aggregation was assessed by turbidimetric aggre-
ometry using a 4-channel Bio/Data PAP4 aggregometer
Mölab, Langenfield, Germany), as described previously
8). We prepared platelet-rich plasma by centrifugation of
itrated venous blood at 750 g for 2 min and adjusted to 275
o 325  109 thrombocytes/l by dilution with platelet-poor
lasma from the same patient. We used ADP (Sigma,
unich, Germany) to induce aggregation. Light transmis-
ion in platelet-rich plasma was determined 5 min after
ddition of ADP at a final concentration of 5 mol/l.
esults were expressed as percentage of maximal light
ransmission using platelet-poor plasma from the same
atient as reference (100% aggregation). Compared with
aximal light transmission used in some of the previous
tudies (8–10), light transmission at 5 min comprises both
ormation and stability of aggregates but yields a lower read
ut. The coefficient of variation of our optical aggregometry
ssay is 6.1% (8).
utcomes. The primary end point of the study was the
umulative incidence of death from any cause, MI, or urgent
arget lesion revascularization (aortocoronary bypass surgery
r PCI) due to myocardial ischemia within 30 days after
tent placement. The diagnosis of myocardial infarction was
ased on either the development of pathologic Q waves in 2
r more contiguous electrocardiographic leads or an eleva-
ion of creatine kinase or its MB isoenzyme to at least 3
imes the upper limit of normal in at least 2 blood samples.
s a secondary end point, we monitored the plasma
oncentrations of troponin T. We obtained blood sam-
les for determination of creatinine kinase and troponin
before PCI, at 8, 16, and 24 h after PCI (with a 2-h
olerance), and before discharge (36 to 48 h after PCI).
t the same time points, we obtained 12-lead electrocar-
iographic recordings.
In addition, we assessed bleeding complications. Accord-
ng to the TIMI definitions (19), a bleeding event was
efined as major if it was intracranial or if there were
linically significant overt signs of hemorrhage associated
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Effect of Clopidogrel Loading and Risk of PCI November 7, 2006:1742–50ith a drop in hemoglobin of 5 g/dl. To account for
ransfusion, an increase in hemoglobin of 1 g/dl was
ssumed for each unit of blood.
We performed a phone interview at 30 days. For patients
eporting cardiac symptoms, at least one clinical and elec-
rocardiographic examination was performed in the outpa-
ient clinic or by the referring physician. Thirty-day
ollow-up was completed in all patients. All information
erived from contingent hospital readmission records or
rovided by the referring physician or by the outpatient
linic was entered into the computer database. All events
ere classified and adjudicated by a physician not involved
n the follow-up process.
tatistical methods. Sample size calculation was based on
SAR-REACT (6), which comprised a cohort with similar
election criteria and treatment strategy. Thus, we assumed
n incidence of the primary end point of 4.2%. We designed
ur study to test the hypothesis that the incidence of the
rimary end point differed by quartiles of ADP-induced
latelet aggregation. We intended to have a power of 0.80
o detect an effect size of 0.015 (e.g., 3-fold risk in the
ourth quartile) with a 2-sided p value 0.05. With these
ssumptions, we obtained a sample size of at least 748
nQuery Advisor, version 5.0, Statistical Solutions, Cork,
reland) and aimed for a cohort of 800. For all statistical
nalyses, we used the SPSS software package, version 11.5
SPSS, Chicago, Illinois). In general, discrete variables are
eported as counts (percentages) and continuous variables as
ean SD. We tested differences between groups with the
hi-square test for discrete variables and with 1-way analysis
f variance for continuous variables. In case of a highly
kewed distribution of a continuous variable (skewness 2),
e tested differences between groups by the Kruskal-Wallis
est and report this variable as median (interquartile range).
vent-free survival was analyzed by the Kaplan-Meier
ethod, and differences in event-free survival were assessed
y means of the log rank test. We calculated various
nivariable and multivariable logistic regression models for
he primary end point as dependent variable. To control for
otential confounders, the multivariable models included
emographic, clinical and angiographic variables (Table 1)
ith a difference between quartiles of aggregation at p 
.20. In addition, we added time from clopidogrel loading
nd baseline platelet aggregation to the model. To identify
actors that correlate with platelet aggregation immediately
efore intervention, we performed univariable and multiva-
iable analyses with platelet aggregation as a continuous
ariable using the general linear model. Apart from baseline
latelet aggregation and percentage inhibition of platelet
ggregation, the multivariable model included as factors and
ovariables any demographic, clinical, and angiographic
ariable (Table 1) that in univariable models showed an
ssociation with platelet aggregation immediately before
CI at p 0.20. In the 2-tailed test, a p value of0.05 wasegarded as significant. CESULTS
tudy population. Figure 1 shows the trial profile. The
tudy cohort comprised 802 patients. Table 1 shows the
emographic and baseline clinical characteristics of the
tudy cohort as well as the procedural and angiographic
ariables.
Thirty-day follow-up was completed in all patients. As
hown in Table 2, 15 patients incurred 19 major adverse
ardiac events within 30 days. After PCI, troponin T
oncentrations above the detection limit (0.03 g/l) were
ound in 34.4% of the patients, but in only 7.5% troponin T
ncreased to more than 10 times the detection limit (Table 2).
wo patients received abciximab for bail-out.
hirty-day event rate according to quartiles of ADP-
nduced platelet aggregation. Immediately before PCI,
edian ADP-induced (5 mol/l) platelet aggregation was
4% with an interquartile range of 4% to 32%. As shown in
igure 2 and Table 2, the incidence of MACE during
0-day follow-up increased with quartiles of ADP-induced
latelet aggregation. It was 0.5% in the 2 quartiles with the
owest platelet aggregation, but 3.1% in the third quartile
nd 3.5% in the highest quartile (p  0.034). Thus, platelet
ggregation above median was associated with a relative risk
or 30-day MACE of 6.71 (95% confidence interval [CI]
.52 to 29.41) (p  0.003).
As shown in Table 2, quartiles of platelet aggregation
ere not significantly associated with postprocedural eleva-
ions in troponin T or the composite 30-day incidence of
ACE and post-procedural elevations in troponin T.
ikewise, bleeding and vascular access site complications as
ell as the composite incidence of cardiac and noncardiac
omplications did not vary significantly with the level of
DP-induced platelet aggregation (Table 2).
The majority of the demographic, baseline clinical, pro-
edural, and angiographic variables did not differ signifi-
antly between quartiles of platelet aggregation. Patients in
he higher quartiles were, however, significantly older and
ad a significantly higher body mass index. Likewise, the
roportion of patients with diabetes mellitus and impaired
eft ventricular function increased significantly with increas-
ng quartiles of platelet aggregation, whereas the count of
rug-eluting stents implanted decreased significantly. There
ere trends toward a higher proportion of active smokers
nd of patients with hypertension or with non-left anterior
escending PCI and a trend toward a lower percentage
iameter stenosis before PCI in the higher quartiles. After
djustment for these variables in a multivariable logistic
egression model, platelet aggregation above median was
ssociated with an adjusted odds ratio for 30-day MACE of
.2 (95% CI 1.6 to 33.8) (p  0.011) (Fig. 3A).
As shown in Table 3, patients belonging to the strata
ith the higher ADP-induced platelet aggregation before
ntervention more often underwent PCI within 2 h after
oading with clopidogrel than patients in the lower strata.
onversely, the proportion of patients with an ADP-
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November 7, 2006:1742–50 Effect of Clopidogrel Loading and Risk of PCInduced platelet aggregation above 14%, the median of
he entire cohort, varied significantly with time after
lopidogrel loading (Fig. 4). To adjust the odds ratio for
0-day MACE for time from clopidogrel loading, we
ncluded this variable in the multivariable logistic regres-
ion model, which yielded an adjusted odds ratio for
0-day MACE of 9.6 (95% CI 2.1 to 44.3) (p  0.004)
Fig. 3A).
Patients belonging to the strata with the lower ADP-
nduced platelet aggregation before intervention also had a
ignificantly lower platelet aggregation at baseline (Table 3).
e therefore calculated a third multivariable logistic regres-
ion model which also included baseline platelet aggrega-
able 1. Baseline Demographic, Clinical, and Angiographic Cha
latelet Aggregation
Entire
Cohort
(n  802)
1st Quart
(<4%)
(n  209
ge (yrs) 66.4  9.1 65.1  9.3
omen 175 (21.8) 53 (25.4
ctive smoker 87 (10.8) 15 (7.2)
rterial hypertension 660 (82.3) 163 (78.0
iabetes mellitus 199 (24.8) 40 (19.1
otal cholesterol (mmol/l) 5.1  1.2 5.2  1.2
ody mass index (kg/m2) 27.7  3.9 27.0  3.6
latelets (109/l) 216  55.8 220  55
spirin 802 (100) 209 (100
eta-blockers 555 (69.2) 149 (71.3
CE inhibitors 342 (42.6) 83 (39.7
itrates 239 (29.8) 60 (28.7
tatins 455 (56.7) 119 (56.9
revious balloon angioplasty 274 (34.2) 69 (33.0
revious CABG 112 (14.0) 28 (13.4
revious myocardial infarction 184 (22.9) 43 (20.6
mpaired LV function* 287 (35.8) 58 (28.8
CS angina class III or IV 199 (24.9) 54 (25.9
ultivessel PCI 178 (22.2) 48 (23.0
tents implanted 1.8  1.0 1.8  1.0
rug-eluting stents implanted 0.4  0.6 0.5  0.6
HA/ACC lesion type (B2 or C) 528 (66.5) 139 (67.5
tented segment
Left main coronary artery 18 (2.2) 6 (2.9)
Left anterior descending artery 367 (45.8) 109 (52.2
Circumflex artery 295 (36.8) 69 (33.0
Right coronary artery 281 (35.0) 69 (33.0
Bypass graft 25 (3.1) 4 (1.9)
CA analysis
Vessel size (mm) 2.85  0.65 2.81  0.5
Before PCI
Minimal luminal diameter (mm) 0.72  0.50 0.71  0.4
Diameter stenosis (%) 74.8  15.9 74.9  15
Stenosis length (mm) 10.2  5.2 10.2  5.1
Balloon size (mm) 3.2  0.5 3.2  0.4
Inflation pressure (atm) 13.8  2.8 13.5  2.4
After PCI
Minimal luminal diameter (mm) 2.76  0.46 2.76  0.4
Diameter stenosis (%) 9.3  6.6 8.5  6.1
ata are expressed as mean value  SD or number of patients (percentage). The p val
entricular ejection fraction 55%.
ACE  angiotensin-converting enzyme; AHA/ACC  American Heart Associa
anadian Cardiovascular Society; LV  left ventricular; PCI  percutaneous coronion. In this model, the strong association between platelet wggregation at the time of intervention and 30-day MACE
revailed (Fig. 3A).
eterminants of ADP-induced platelet aggregation be-
ore intervention. In a 2-variable model, the variability in
aseline platelet aggregation accounted for 32% and that of
he inhibition of platelet aggregation from baseline to
mmediately before PCI for 56% of the variability in
DP-induced platelet aggregation before intervention.
ime from clopidogrel loading had a strong impact on the
hange in platelet aggregation. In patients with a time from
lopidogrel loading of 2 h, the percentage inhibition of
DP-induced platelet aggregation from baseline to imme-
iately before PCI was 39 54%, whereas it was 62 53%
istics of the Entire Study Cohort and According to Quartiles of
2nd Quartile
(4–14%)
(n  198)
3rd Quartile
(15–32%)
(n  196)
4th Quartile
(>32%)
(n  199) p Value
66.5  9.1 66.2  9.0 67.9  8.9 0.02
42 (21.2) 40 (20.4) 40 (20.1) 0.54
21 (10.6) 30 (15.3) 21 (10.6) 0.06
159 (80.3) 169 (86.2) 169 (84.9) 0.10
42 (21.2) 61 (31.1) 56 (28.1) 0.02
5.2  1.2 5.1  1.2 5.0  1.1 0.28
27.7  3.8 27.9  4.3 28.3  3.8 0.01
212  55.2 221  51.5 212  59.0 0.37
198 (100) 196 (100) 199 (100) 1.00
133 (67.2) 132 (67.3) 141 (70.9) 0.71
87 (43.9) 89 (45.4) 83 (41.7) 0.67
58 (29.3) 59 (30.1) 62 (31.2) 0.96
114 (57.6) 111 (56.6) 111 (55.8) 0.99
73 (36.9) 66 (33.7) 66 (33.2) 0.83
29 (14.6) 24 (12.2) 31 (15.6) 0.79
50 (25.3) 45 (23.0) 46 (23.1) 0.74
70 (35.4) 80 (40.8) 78 (39.4) 0.03
54 (27.3) 45 (23.0) 46 (23.1) 0.91
45 (22.7) 43 (21.9) 42 (21.1) 0.97
1.7  1.0 1.9  1.1 1.8  1.1 0.66
0.4  0.6 0.4  0.6 0.4  0.7 0.02
124 (63.6) 135 (69.2) 130 (65.7) 0.67
5 (2.5) 4 (2.0) 3 (1.5) 0.81
83 (41.9) 91 (46.4) 86 (42.2) 0.13
75 (37.9) 80 (40.8) 71 (35.7) 0.42
72 (36.4) 62 (31.6) 78 (39.2) 0.39
7 (3.5) 5 (2.6) 9 (4.5) 0.45
2.90  0.58 2.90  0.56 2.90  0.60 0.62
0.77  0.50 0.74  0.50 0.80  0.47 0.37
73.7  15.3 73.7  16.2 72.6  14.6 0.20
10.4  5.1 10.3  5.0 10.0  5.6 0.59
3.2  0.5 3.2  0.4 3.2  0.5 0.39
13.8  2.8 13.7  2.7 14.1  3.1 0.21
2.80  0.46 2.72  0.43 2.79  0.50 0.91
8.8  6.9 9.7  6.9 9.4  6.4 0.40
ermined by 1-way ANOVA or chi-square test between quartiles of aggregation. *Left
merican College of Cardiology; CABG  coronary artery bypass grafting; CCS 
ervention; QCA  quantitative coronary angiography.racter
ile
)
)
)
)
.9
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
4
8
.4
4
ues detith a delay of more than 2 h (p  0.001). Apart from
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Effect of Clopidogrel Loading and Risk of PCI November 7, 2006:1742–50aseline platelet aggregation, percentage inhibition of platelet
ggregation immediately before PCI and time from clopi-
ogrel loading (PCI within the first 2 h after loading dose),
ge, hypertension, diabetes, body mass index, and number of
rug-eluting stents were significantly (p  0.05) related to
latelet aggregation in univariable models. In addition, total
holesterol, reduced left ventricular function, stent in left
nterior descending coronary artery, and balloon pressure
uring PCI were correlated with platelet aggregation by trend
p  0.20). These variables were entered in the multivariable
eneral linear model (Table 4). In this model, baseline platelet
ggregation and percentage inhibition of platelet aggregation
rom baseline to immediately before PCI prevailed as the
trongest predictor of platelet aggregation, accounting for 30%
Figure 1. Trial profile. ASA  aspirin;
able 2. Cardiac and Noncardiac Events Within 30 Days in the En
Entire
Cohort
(n  802)
1st Quart
(<4%)
(n  20
eath 3 (0.4) 0 (0.0)
-wave MI 4 (0.5) 0 (0.0)
on–Q-wave MI 4 (0.5) 1 (0.5)
LR 8 (1.0) 1 (0.5)
ny MACE 15 (1.9) 1 (0.5)
roponin T 0.03–0.10 g/l 124 (15.5) 36 (17.2
roponin T 0.10–0.30 g/l 92 (11.5) 24 (11.5
roponin T 0.30 g/l 60 (7.5) 12 (5.7)
ny troponin T 0.03 g/l 276 (34.4) 72 (34.4
ny MACE or troponin T 0.03 g/l 281 (35.0) 72 (34.4
IMI major bleed 8 (1.0) 3 (1.4)
alse aneurysm 28 (3.5) 5 (2.4)
ransfusion 4 (0.5) 1 (0.5)
ny MACE or major bleed 21 (2.6) 4 (1.9)
ata are expressed as number of patients (percentage). The p values determined by
MACE  major adverse cardiac event; MI  nonfatal myocardial infarction defined as
n MB isoenzyme with or without new Q-wave; TIMI  Thrombolysis In Myocardial Innd 53%, respectively, of the variability in ADP-induced
latelet aggregation immediately before PCI.
To corroborate our analyses based on strata of ADP-
nduced platelet aggregation before intervention, we calcu-
ated multivariable logistic regression models with ADP-
nduced platelet aggregation before intervention entered as a
ontinuous variable and performed stepwise adjustment for
ts determinants. As shown in Figure 3B, these models
onfirmed the primary analyses. After adjustments for demo-
raphic, clinical and angiographic variables as well as for time
rom clopidogrel loading and baseline platelet aggregation, a
0% increase in ADP-induced platelet aggregation before
ntervention was associated with an adjusted odds ratio for
0-day MACE of 1.32 (95% CI 1.04 to 1.61) (p  0.026).
 percutaneous coronary intervention.
tudy Cohort and According to Quartiles of Platelet Aggregation
2nd Quartile
(4–14%)
(n  198)
3rd Quartile
(15–32%)
(n  196)
4th Quartile
(>32%)
(n  199) p Value
0 (0.0) 0 (0.0) 3 (1.5) 0.03
0 (0.0) 3 (1.5) 1 (0.5) 0.10
1 (0.5) 2 (1.0) 0 (0.0) 0.56
0 (0.0) 4 (2.0) 3 (1.5) 0.15
1 (0.5) 6 (3.1) 7 (3.5) 0.03
28 (14.1) 22 (11.2) 38 (19.1) 0.14
23 (11.6) 26 (13.3) 19 (9.5) 0.72
12 (6.1) 19 (9.7) 17 (8.5) 0.36
63 (31.8) 67 (34.2) 74 (37.2) 0.74
63 (31.8) 67 (34.2) 79 (39.7) 0.41
2 (1.0) 2 (1.0) 1 (0.5) 0.83
9 (4.5) 7 (3.6) 7 (3.5) 0.74
1 (0.5) 2 (1.0) 0 (0.0) 0.56
3 (1.5) 7 (3.6) 7 (3.5) 0.44
uare test between groups of aggregation.tire S
ile
9)
)
)
)
)
chi-sq
rise in creatinine kinase to 3 times the upper limit of normal with concomitant rise
farction; TLR  target lesion revascularization.
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.31 (95% CI 1.03 to 1.67) (p  0.026).
ISCUSSION
his prospective study demonstrated the clinical relevance
f the variability of platelet aggregation after the 600-mg
oading dose of clopidogrel in patients undergoing elective
CI. The 30-day incidence of MACE after elective PCI
ncreased significantly with quartiles of ADP-induced plate-
et aggregation. It was 0.5% in the 2 quartiles with the
owest platelet aggregation, but 3.1% and 3.5% in the third
nd fourth quartiles, respectively. We, thus, found a sub-
tantial difference in the 30-day incidences of MACE
etween patients with a platelet aggregation above or below
igure 2. Cumulative incidence of major adverse cardiac events (MACE)
ithin 30 days after percutaneous coronary intervention (PCI) by quartiles
f adenosine diphosphate-induced platelet aggregation. p value determined
y log-rank test.
igure 3. Odds ratios for 30-day major adverse cardiac events (MACE) an
iphosphate (ADP)-induced platelet aggregation above median (A) or abso
ntervention (PCI) as independent variable. *Demographic, clinical, and angiogra
t p  0.20. †Demographic, clinical, and angiographic variables of Table 4.edian, but very similar incidences within the 2 lowest and
he 2 highest quartiles. Although event rates were low
rrespective of the level of platelet aggregation, an ADP-
nduced platelet aggregation above median was associated
ith a more than 6-fold increase in risk of early MACE
ompared with a platelet aggregation below median. Our
rospective study identified platelet function assessed before
ntervention as a strong independent prognostic factor in
atients who receive pre-treatment 600 mg clopidogrel.
The observed variability in residual platelet aggregation
mmediately before PCI depends by 30% on the interindi-
idual variability in platelet function even before the initi-
tion of clopidogrel and by just above 50% on the variability
n platelet responses to clopidogrel loading. An adequate
elay from loading is critical to the clopidogrel effect at the
ime of PCI: the proportion of patients with suboptimal
nhibition of platelet aggregation during PCI (i.e., platelet
ggregation above median of entire cohort) varied consid-
rably with time after loading, from 66.5% in those under-
oing catheterization within 2 h after loading to 41.8% in
hose with a longer delay. This finding is consistent with
arlier studies (8) demonstrating that after a 600-mg load-
ng dose of clopidogrel 2 h are needed before a full (or
ear-full) effect is achieved. It is noteworthy that the
roportion of patients with suboptimal platelet inhibition is
till large even after a sufficient (i.e., 2 h) wait and that,
onsistent with our earlier study (8), an additional delay
oes not noticeably reduce this proportion.
The question arises whether the relation between MACE
nd platelet aggregation at the time of PCI can be attributed
o the variability of time from clopidogrel loading or to
aseline aggregation and whether it is independent of
onfounding baseline variables. To this end we calculated
confidence intervals in various logistic regression models with adenosine
DP-induced platelet aggregation (B) at the time of percutaneous coronaryd 95%
lute Aphic variables of Table 1 with a difference between quartiles of aggregation
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tep we adjusted for demographic, clinical, and angiographic
ovariables, which demonstrated an independent relation
etween MACE and platelet aggregation at the time of
CI. This confirmed that the variability in platelet aggre-
ation at the time of PCI, irrespective of its cause, is
elevant to clinical outcome. In a second and third step, we
lso adjusted for time from clopidogrel loading and baseline
ggregation. In these models, the significant independent
elation between MACE and platelet aggregation at the
ime of PCI prevailed. In the aggregate, the multivariable
nalyses demonstrate that the underlying biologic differ-
nces in response to clopidogrel are relevant to clinical
utcome, rather than simply the differences in baseline
haracteristics or differences in time of exposure to clopi-
ogrel before PCI.
In addition to the findings of the GOLD study on GP
Ib/IIIa blockade (5), several clinical observations suggested
hat the peri-interventional level of platelet inhibition is
rucial to the prevention of early complications after PCI. In
ARGET (Do Tirofiban and ReoPro Give Similar Efficacy
utcomes Trial), differences in 30-day outcome after PCI
etween tirofiban and abciximab could be attributed to
ifferences in the level of platelet inhibition at the time of
CI (20). Other studies reported consistent results for
igure 4. Percentage of patients with aggregation above median stratified
ccording to various clusters of time after clopidogrel loading. Error bars
epresent 95% confidence intervals. Number of patients within the cluster
nd percentage of the entire cohort are given below the columns. The p
alues for comparison between clusters of time were determined by
hi-square test. ADP  adenosine diphosphate; PCI  percutaneous
able 3. Time From Loading, Baseline Aggregation, and Inhibit
ercutaneous Coronary Intervention (PCI)
Entire
Cohort
(n  802)
1st Quarti
(<4%)
(n  209
ime from loading dose to PCI 3.1 (1.7–5.3) 4.2 (2.5–6.
CI within first 2 h after loading 242 (30.2) 32 (15.3)
aseline aggregation (%) 46  17 40  18
nhibition of aggregation (%) 67 (31–90) 98 (94–10
ime from loading dose to PCI and inhibition of aggregation are expressed as medi
ean value  standard deviation with p determined by 1-way ANOVA, and PCI with
uartiles of aggregation. Percentage inhibition of aggregation was calculated as [(basporonary intervention.hienopyridines by showing that the early outcome of PCI is
uperior if the thienopyridine is effective at the time of PCI
han if it is started immediately after PCI (3,4). More
ecently, the ARMYDA (Antiplatelet Therapy for Reduc-
ion of Myocardial Damage During Angioplasty) study
eported a more favorable 30-day outcome after pre-
reatment with 600 mg than after pre-treatment with 300
g clopidogrel (18).
Pursuing the concept that adequate peri-interventional
latelet inhibition is critical, the present study focused on
he impact of the peri-interventional level of platelet aggre-
ation. To our knowledge, it provides the first prospective
ata that the peri-interventional level of platelet aggregation
fter loading with 600 mg clopidogrel is related to the
utcome of elective PCI in low- to intermediate-risk pa-
ients. Most of the events that could be related to the level
f platelet aggregation were detected within 48 h after PCI,
ut 4 events occurred between days 3 and 11. These
ubacute events may be interpreted as a late sequel of
nsufficient peri-interventional platelet inhibition or as a
onsequence of an inadequate suppression of platelet func-
ion that continues during chronic therapy. The latter
nterpretation is supported by recent retrospective studies
hat reported low levels of platelet inhibition under chronic
reatment with clopidogrel in patients presenting with late
tent thrombosis (21,22).
tudy limitations. Compared with previous studies
1,2,6,23,24), the incidence of MACE in the current study,
n particular that of MI, was remarkably low. For most
revious studies (1,2,23,24), a large extent of this difference
an be attributed to technologic advances and to differences
n patient selection, with the exclusion of higher-risk
atients in the present study. We used, however, the same
nterventional approach and the same selection criteria as
SAR-REACT (6), the study which our power calculation
as based on. Consequently, most of the baseline charac-
eristics were similar in our study and, notably, two-thirds of
he lesions treated in both studies were complex (AHA/
CC lesion type B2 or C). The proportion of patients with
lass III/IV angina was, however, higher in ISAR-REACT
40% vs. 25% in the present study), which may have
ontributed to the lower event rate in our cohort. The fact
hat the event rate was lower than projected reduces the
ccording to Quartiles of Platelet Aggregation Before
2nd Quartile
(4–14%)
(n  198)
3rd Quartile
(15–32%)
(n  196)
4th Quartile
(>32%)
(n  199) p Value
3.2 (2.0–5.2) 3.2 (1.8–5.3) 1.8 (0.9–4.0) 0.001
49 (24.7) 59 (30.1) 102 (51.3) 0.001
44  16 47  15 55  15 0.001
81 (72–95) 52 (36–65) 16 (0–29) 0.001
terquartile range) with p determined by Kruskal-Wallis test, baseline aggregation as
t 2 h after loading as count (percentage) with p determined by chi-square test between
ggregation  aggregation at PCI)/(baseline aggregation)]  100.ion A
le
)
5)
0)
an (inower of the present study. The limited number of events
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latelet aggregation above which patients need to be con-
idered at high risk.
Similar to other studies (25,26), about one-third of our
atients incurred minor myocardial necroses, as evidenced
y peri-interventional increases in cardiac troponin T. We
ould not detect any significant relation between minor
yocardial necroses and any of the platelet function vari-
bles that we assessed in this study, although the power to
etect such relation would have been high. One potential
xplanation for insensitivity could be that minor myocardial
ecroses are not a platelet-related event. As alternative
echanisms, one may consider distal embolization of
laque material or inadvertent obstruction of small side
ranches.
linical implications. Most of the patients included in
his study had a low risk profile. In patients with higher risk,
uboptimal platelet inhibition may become even more im-
ortant. Specifically, this appears to be true in patients with
cute coronary syndromes, as suggested by a recent small
tudy (27). This study showed poor outcome of PCI in
cute myocardial infarction if platelet inhibition by clopi-
ogrel was inadequate. Consistently, ISAR-REACT-2 re-
ealed that in high-risk acute coronary syndromes, clopi-
ogrel alone does not afford sufficient protection against
ost-interventional ischemic events and that abciximab is
till needed to optimize outcome in this setting (15).
oreover, with the more widespread use of drug-eluting
tents an increasing proportion of patients with high-risk
ngiographic features will undergo PCI. The risk of such
nterventions may become prohibitive if platelet inhibition
s suboptimal.
The results of the present study, therefore, encourage the
earch for improved treatment regimens that give a more
obust platelet inhibition or for new P2Y12 receptor antag-
nists that offer a rapid efficacious and predictable platelet
nhibition. In this respect, our study strongly endorses the
se of adequate loading dosages of clopidogrel with ade-
uate delays before PCI. This will solve only part of
Table 4. Multivariable General Linear Model
Immediately before PCI as Dependent Variabl
Independent Variable Coeffici
Baseline platelet aggregation (%) 0.4
Inhibition of aggregation before PCI (%) 0.2
PCI within 2 h after loading 5.4
Age (yrs) 0.0
Total cholesterol (mmol/l) 0.3
Diabetes mellitus 0.0
Arterial hypertension 0.3
Body mass index (kg/m2) 0.3
Impaired LV function 0.0
Stent in LAD 1.2
Inflation pressure (atm) 0.3
Drug-eluting stents implanted 0.0
ADP  adenosine diphosphate; LAD  left anterior descen
coronary intervention.roblem, however, because around 40% of the patients willtill undergo PCI without optimal platelet inhibition. More
ecently, the use of loading dosages of clopidogrel even
igher than 600 mg has been tested but showed no
ignificant improvement (28,29). The newer P2Y12 receptor
ntagonists appear promising, but the ongoing phase 3 trials
ave to be awaited before they can enter clinical practice
30). While clopidogrel is still in use, our study suggests
hat, at least in high-risk patients, screening and correction
f inadequate platelet inhibition can improve outcome.
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